» Articles » PMID: 30895640

Low-grade Oncocytic Tumour of Kidney (CD117-negative, Cytokeratin 7-positive): a Distinct Entity?

Overview
Journal Histopathology
Date 2019 Mar 22
PMID 30895640
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To describe a group of distinct low-grade oncocytic renal tumours that demonstrate CD117 negative/cytokeratin (CK) 7-positive immunoprofile.

Methods And Results: We identified 28 such tumours from four large renal tumour archives. We performed immunohistochemistry for: CK7, CD117, PAX8, CD10, AMACR, e-cadherin, CK20, CA9, AE1/AE3, vimentin, BerEP4, MOC31, CK5/6, p63, HMB45, melan A, CD15 and FH. In 14 cases we performed array CGH, with a successful result in nine cases. Median patient age was 66 years (range 49-78 years) with a male-to-female ratio of 1:1.8. Median tumour size was 3 cm (range 1.1-13.5 cm). All were single tumours, solid and tan-brown, without a syndromic association. On microscopy, all cases showed solid and compact nested growth. There were frequent areas of oedematous stroma with loosely arranged cells. The tumour cells had oncocytic cytoplasm with uniformly round to oval nuclei, but without significant irregularities, and showed only focal perinuclear halos. Negative CD117 and positive CK7 reactivity were present in all cases (in two cases there was focal and very weak CD117 reactivity). Uniform reactivity was found for PAX8, AE1/AE3, e-cadherin, BerEP4 and MOC31. Negative stains included CA9, CK20, vimentin, CK5/6, p63, HMB45, Melan A and CD15. CD10 and AMACR were either negative or focally positive; FH was retained. On array CGH, there were frequent deletions at 19p13.3 (seven of nine), 1p36.33 (five of nine) and 19q13.11 (four of nine); disomic status was found in two of nine cases. On follow-up (mean 31.8 months, range 1-118), all patients were alive with no disease progression.

Conclusion: Low-grade oncocytic tumours that are CD117-negative/CK7-positive demonstrate consistent and readily recognisable morphology, immunoprofile and indolent behaviour.

Citing Articles

Whole exome sequencing identified mutations of forkhead box I 1 (FOXI1), keratin 6 C (KRT6C) and gap junction protein delta 2 (GJD2) in a low-grade oncocytic tumor of the kidney: a case report.

Kakumoto A, Nishimura K, Toki D, Kasajima R, Kuroda H, Nagashima Y Diagn Pathol. 2025; 20(1):21.

PMID: 39980061 PMC: 11844160. DOI: 10.1186/s13000-025-01616-3.


Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists.

Mohanty S, Lobo A, Jha S, Sangoi A, Akgul M, Trpkov K Virchows Arch. 2024; 485(5):829-840.

PMID: 39287823 PMC: 11564393. DOI: 10.1007/s00428-024-03909-2.


Low-grade oncocytic tumor of the kidney: imaging features of a novel tumor entity.

Bodard S, Delavaud C, Dariane C, Boudhabhay I, Bensenouci N, Timsit M Abdom Radiol (NY). 2024; 49(12):4307-4323.

PMID: 39068611 DOI: 10.1007/s00261-024-04487-2.


Diagnostic Biomarkers in Renal Cell Tumors According to the Latest WHO Classification: A Focus on Selected New Entities.

Sanguedolce F, Mazzucchelli R, Falagario U, Cormio A, Zanelli M, Palicelli A Cancers (Basel). 2024; 16(10).

PMID: 38791935 PMC: 11120103. DOI: 10.3390/cancers16101856.


The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates.

Goswami P, Singh G, Patel T, Dave R Cureus. 2024; 16(4):e58470.

PMID: 38765391 PMC: 11100973. DOI: 10.7759/cureus.58470.